Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
Axogen, Inc. director Wendell Amy McBride acquired 14,150 shares of common stock through the vesting and conversion of restricted stock units on June 19, 2026. These RSUs were an annual equity grant for Board service, valued at $150,000 as of the grant date.
Each vested unit converted into one share of Axogen common stock, increasing McBride’s directly held position to 107,976 shares after the transaction. This is a compensation-related derivative exercise, not an open-market purchase or sale.
Axogen, Inc. director THOMAS PAUL acquired 18,867 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 18,867 restricted stock units converted into an equal number of common shares as they vested, reflecting an annual equity grant for service on the Board.
The equity grant was based on a $200,000 valuation as of the original grant date and vested on the one-year anniversary of that date. Following this vesting and conversion, Paul directly holds 32,395 shares of Axogen common stock.
TYNDALL JOSEPH A. reported acquisition or exercise transactions in this Form 4 filing.
Axogen, Inc. director Joseph A. Tyndall reported the vesting of 14,150 restricted stock units on June 19, 2026, which were settled into 14,150 shares of common stock. Each restricted stock unit represented a right to receive one share upon vesting, reflecting an annual equity grant for board service valued at $150,000 on the grant date. This filing shows a compensation-related equity award vesting, not an open-market stock purchase or sale.
Axogen, Inc. director John Johnson acquired 14,150 shares of common stock through the vesting and conversion of 14,150 restricted stock units on June 19, 2026. Each restricted stock unit represented a right to receive one Axogen common share. These RSUs were an annual equity grant for board service, based on a $150,000 valuation at the grant date and scheduled to vest on the one-year anniversary of that grant.
Axogen, Inc. director William P. Burke reported a routine equity compensation event. On June 19, 2026, 14,150 restricted stock units vested and were delivered as 14,150 shares of common stock, reflecting an annual equity grant for his service on the Board of Directors.
Each restricted stock unit represented a right to receive one share of Axogen common stock. Following this vesting and conversion, Burke directly holds 14,250 shares of common stock. No open-market purchases or sales were reported, and there are no remaining derivative holdings from this RSU grant.
Axogen, Inc. director Wendell Amy McBride exercised stock options and sold the resulting shares. On May 8, 2026, she exercised options covering 1,647 shares of common stock at $14.85 per share, then completed an open-market sale of 1,647 shares at a weighted average price of $42.60 per share, with individual sale prices ranging from $42.50 to $42.62. After these transactions, she directly held 93,826 shares of Axogen common stock.
Axogen, Inc. director John Johnson exercised stock options and sold the resulting shares. On May 7, 2026, he exercised options covering 11,050 shares of common stock at $7.04 per share, then sold 11,050 shares in open-market transactions at a weighted average price of $43.255 per share. The sale price reflected multiple trades between $43.25 and $43.35 per share. Following these transactions, Johnson reported holding 0 shares of Axogen common stock directly, and the exercised option grant was fully used.
Axogen, Inc. director Kathy Johnson Weiler exercised options to acquire 16,344 shares of common stock at $6.95 per share, then sold the same 16,344 shares in an open‑market transaction at a weighted average price of $44.091 per share on May 7, 2026.
Following these transactions, she reports holding no common shares directly but retains 27,307 employee stock options with a $6.95 exercise price expiring on December 20, 2033. According to the grant terms, these options vest in three equal annual installments beginning on December 20, 2024.
Axogen, Inc. Chief Marketing Officer Jens Kemp reported an open-market sale of 4,000 shares of Axogen common stock. The weighted average sale price was $43.4403 per share, with individual trades executed between $43.44 and $43.45 per share. Following these transactions, Kemp directly owns 72,451 shares of Axogen common stock.